All data are based on the daily closing price as of June 27, 2025
j

JCR Pharmaceuticals

4552.TSE
3.57 USD
0.00
0.00%

Overview

Last close
3.57 usd
Market cap
434.55M usd
52 week high
7.64 usd
52 week low
2.69 usd
Target price
5.42 usd

Valuation

P/E
N/A
Forward P/E
23.2558
Price/Sales
1.8972
Price/Book Value
1.3339
Enterprise Value
605.93M usd
EV/Revenue
2.6504
EV/EBITDA
10.259

Key financials

Revenue TTM
228.62M usd
Gross Profit TTM
150.28M usd
EBITDA TTM
-23.97M usd
Earnings per Share
-0.27 usd
Dividend
0.14 usd
Total assets
703.30M usd
Net debt
167.07M usd

About

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is based in Ashiya, Japan.
  • Symbol
    4552.TSE
  • Exchange
    TSE
  • Isin
    JP3701000006
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Shin Ashida
  • Headquarter
    Ashiya
  • Web site
    https://www.jcrpharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top